Literature DB >> 21326808

NPM-ALK and the JunB transcription factor regulate the expression of cytotoxic molecules in ALK-positive, anaplastic large cell lymphoma.

Joel D Pearson1, Jason K H Lee, Julinor T C Bacani, Raymond Lai, Robert J Ingham.   

Abstract

Anaplastic lymphoma kinase-positive, anaplastic large cell lymphoma (ALK+ ALCL) is an aggressive non-Hodgkin lymphoma of T/null immunophenotype that is most prevalent in children and young adults. The normal cellular counterpart of this malignancy is presumed to be the cytotoxic T lymphocyte (CTL), and this presumption is partly based on the observation that these tumour cells often express cytotoxic granules containing Granzyme B (GzB) and Perforin. Chromosomal translocations involving the gene encoding for the ALK tyrosine kinase are also characteristic of ALK+ ALCL, and the resulting fusion proteins (e.g. NPM-ALK) initiate signalling events important in ALK+ ALCL pathogenesis. These events include the elevated expression of JunB; an AP-1 family transcription factor that promotes ALK+ ALCL proliferation. In this report we demonstrate that JunB is a direct transcriptional activator of GzB and that GzB transcription is also promoted by NPM-ALK. We found that Perforin expression was not regulated by JunB, but was promoted by NPM-ALK in some cell lines and inhibited by it in others. In conclusion, our study makes the novel observation that signalling through NPM-ALK and JunB affect the expression of cytotoxic molecules in ALK+ ALCL. Moreover, these findings demonstrate the expression of GzB and Perforin in this lymphoma is not solely due its presumed CTL origin, but that oncogenic signalling is actively influencing the expression of these proteins.

Entities:  

Keywords:  ALK+ ALCL; JunB; NPM-ALK; granzyme B; perforin

Mesh:

Substances:

Year:  2011        PMID: 21326808      PMCID: PMC3037198     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  32 in total

1.  JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and reed-sternberg cells of Hodgkin lymphoma.

Authors:  Mariko Watanabe; Masataka Sasaki; Kinji Itoh; Masaaki Higashihara; Kazuo Umezawa; Marshall E Kadin; Lawrence J Abraham; Toshiki Watanabe; Ryouichi Horie
Journal:  Cancer Res       Date:  2005-09-01       Impact factor: 12.701

2.  The Epstein-Barr virus protein, latent membrane protein 2A, co-opts tyrosine kinases used by the T cell receptor.

Authors:  Robert J Ingham; Judith Raaijmakers; Caesar S H Lim; Geraldine Mbamalu; Gerald Gish; Fu Chen; Liudmila Matskova; Ingemar Ernberg; Gösta Winberg; Tony Pawson
Journal:  J Biol Chem       Date:  2005-08-08       Impact factor: 5.157

3.  A cytotoxic phenotype does not predict clinical outcome in anaplastic large cell lymphomas.

Authors:  D F Dukers; R L ten Berge; J J Oudejans; K Pulford; D Hayes; J F Miseré; G J Ossenkoppele; L H Jaspars; R Willemze; C J Meijer
Journal:  J Clin Pathol       Date:  1999-02       Impact factor: 3.411

4.  JunB expression is a common feature of CD30+ lymphomas and lymphomatoid papulosis.

Authors:  George Z Rassidakis; Athanasios Thomaides; Coralyn Atwell; Richard Ford; Dan Jones; Francois-Xavier Claret; L Jeffrey Medeiros
Journal:  Mod Pathol       Date:  2005-10       Impact factor: 7.842

5.  ALK+ lymphoma: clinico-pathological findings and outcome.

Authors:  B Falini; S Pileri; P L Zinzani; A Carbone; V Zagonel; C Wolf-Peeters; G Verhoef; F Menestrina; G Todeschini; M Paulli; M Lazzarino; R Giardini; A Aiello; H D Foss; I Araujo; M Fizzotti; P G Pelicci; L Flenghi; M F Martelli; A Santucci
Journal:  Blood       Date:  1999-04-15       Impact factor: 22.113

6.  The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner.

Authors:  Faye Yuan-Yi Hsu; Patrick B Johnston; Kathleen A Burke; Yi Zhao
Journal:  Cancer Res       Date:  2006-09-15       Impact factor: 12.701

7.  c-Jun expression and activation are restricted to CD30+ lymphoproliferative disorders.

Authors:  Elias Drakos; Vasiliki Leventaki; Ellen J Schlette; Dan Jones; Pei Lin; L Jeffrey Medeiros; George Z Rassidakis
Journal:  Am J Surg Pathol       Date:  2007-03       Impact factor: 6.394

8.  CD30(+) anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology.

Authors:  L Brugières; M C Deley; H Pacquement; Z Meguerian-Bedoyan; M J Terrier-Lacombe; A Robert; C Pondarré; G Leverger; C Devalck; C Rodary; G Delsol; O Hartmann
Journal:  Blood       Date:  1998-11-15       Impact factor: 22.113

9.  Anaplastic large cell lymphomas: a study of 75 pediatric patients.

Authors:  E S G d'Amore; A Menin; E Bonoldi; P Bevilacqua; S Cazzavillan; V Donofrio; C Gambini; M Forni; A Gentile; G Magro; R Boldrini; M Pillon; A Rosolen; R Alaggio
Journal:  Pediatr Dev Pathol       Date:  2007 May-Jun

Review 10.  Recent developments in the transcriptional regulation of cytolytic effector cells.

Authors:  Laurie H Glimcher; Michael J Townsend; Brandon M Sullivan; Graham M Lord
Journal:  Nat Rev Immunol       Date:  2004-11       Impact factor: 53.106

View more
  14 in total

1.  The Cellular Origins of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): Implications for Immunogenesis.

Authors:  Suzanne Dawn Turner
Journal:  Aesthet Surg J       Date:  2019-01-31       Impact factor: 4.283

Review 2.  Expression patterns of the activator protein-1 (AP-1) family members in lymphoid neoplasms.

Authors:  Alexandra Papoudou-Bai; Eleftheria Hatzimichael; Alexandra Barbouti; Panagiotis Kanavaros
Journal:  Clin Exp Med       Date:  2016-09-06       Impact factor: 3.984

3.  Cleavage of the JunB transcription factor by caspases generates a carboxyl-terminal fragment that inhibits activator protein-1 transcriptional activity.

Authors:  Jason K H Lee; Joel D Pearson; Brandon E Maser; Robert J Ingham
Journal:  J Biol Chem       Date:  2013-06-09       Impact factor: 5.157

Review 4.  Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology.

Authors:  Bengt Hallberg; Ruth H Palmer
Journal:  Nat Rev Cancer       Date:  2013-10       Impact factor: 60.716

Review 5.  Anaplastic lymphoma kinase: Role in cancer and therapy perspective.

Authors:  Zhihong Zhao; Vivek Verma; Mutian Zhang
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

6.  The heat shock protein-90 co-chaperone, Cyclophilin 40, promotes ALK-positive, anaplastic large cell lymphoma viability and its expression is regulated by the NPM-ALK oncoprotein.

Authors:  Joel D Pearson; Zubair Mohammed; Julinor T C Bacani; Raymond Lai; Robert J Ingham
Journal:  BMC Cancer       Date:  2012-06-08       Impact factor: 4.430

7.  ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma.

Authors:  Fabrizio Tabbó; Antonella Barreca; Roberto Piva; Giorgio Inghirami
Journal:  Front Oncol       Date:  2012-05-11       Impact factor: 6.244

8.  Anaplastic large cell lymphoma arises in thymocytes and requires transient TCR expression for thymic egress.

Authors:  Tim I M Malcolm; Patrick Villarese; Camilla J Fairbairn; Laurence Lamant; Amélie Trinquand; C Elizabeth Hook; G A Amos Burke; Laurence Brugières; Katherine Hughes; Dominique Payet; Olaf Merkel; Ana-Iris Schiefer; Ibraheem Ashankyty; Shahid Mian; Mariusz Wasik; Martin Turner; Lukas Kenner; Vahid Asnafi; Elizabeth Macintyre; Suzanne D Turner
Journal:  Nat Commun       Date:  2016-01-12       Impact factor: 14.919

9.  NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases.

Authors:  Joel D Pearson; Jason K H Lee; Julinor T C Bacani; Raymond Lai; Robert J Ingham
Journal:  J Signal Transduct       Date:  2012-07-18

10.  Expression of granzyme B sensitizes ALK+ ALCL tumour cells to apoptosis-inducing drugs.

Authors:  Joel D Pearson; Jingxi Zhang; Zuoqiao Wu; Kayla D Thew; Katelynn J Rowe; Julinor T C Bacani; Robert J Ingham
Journal:  Mol Cancer       Date:  2014-08-29       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.